Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01434316
Show Display Options
Rank Status Study
1 Recruiting Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Solid Neoplasm
Interventions: Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib

Study has passed its completion date and status has not been verified in more than two years.